Table 1. Baseline characteristics of eligible studies (N = 33).
| First Author | #* | Year | Country | Ethnicity | Source of Controls | Quality Control | Cancer Type | Case/Control | Genotyping Method | HWE |
|---|---|---|---|---|---|---|---|---|---|---|
| Ahn19 | 2005 | USA | Caucasian | PB | Yes | Breast cancer | 1008/1056 | MALDI-TOF | Yes | |
| Ambrosone20 | 2005 | USA | Mixed | PB | NA | Breast cancer | 279/NA | MALDI-TOF | NA | |
| Aynali21 | 2013 | Turkey | Caucasian | HB | NA | Laryngeal cancer | 25/23 | PCR | Yes | |
| Banescu17 | 2014 | Romania | Caucasian | HB | NA | CML | 168/321 | PCR-RFLP | Yes | |
| Belotte22 | 2015 | USA | Mixed | NA | NA | Ovarian cancer | NA | TaqMan | NA | |
| Bhatti23 | 1 | 2009 | USA | Caucasian | HB | Yes | Glioma | 362/494 | TaqMan | NA |
| Bhatti23 | 2 | 2009 | USA | Caucasian | HB | Yes | Glioblastoma multiforme | 176/494 | TaqMan | NA |
| Bhatti23 | 3 | 2009 | USA | Caucasian | HB | Yes | Meningioma | 134/494 | TaqMan | NA |
| Castaldo12 | 2015 | Portugal | Caucasian | HB | NA | Cervical cancer | 120/107 | PCR | No | |
| Cebrian24 | 2006 | UK | Caucasian | PB | Yes | Breast cancer | 2171/2262 | TaqMan | Yes | |
| Cheng25 | 2011 | USA | mixed | PB | NA | Prostate cancer | 150/761 | PCR | NA | |
| Choi7 | 2007 | USA | Mixed | PB | Yes | Prostate cancer | 508/1403 | MALDI-TOF | Yes | |
| Ding26 | 2012 | China | Asian | PB | NA | Prostate cancer | 1417/1008 | HapMap | Yes | |
| Ezzikouri27 | 2010 | France | Caucasian | HB | Yes | Hepatocellular carcinoma | 96/222 | PCR-RFLP | Yes | |
| Farawela28 | 2012 | Egypt | Caucasian | HB | Yes | NHL | 100/100 | PCR-RFLP | Yes | |
| Funke29 | 2009 | Germany | Caucasian | PB | Yes | Colorectal Cancer | 632/605 | Pyrosequencing Technology | Yes | |
| Geybels6 | 2014 | Netherland | Caucasian | PB | Yes | Prostate cancer | 1527/25184 | PCR | No | |
| He30 | 1 | 2010 | USA | Caucasian | PB | NA | BCC | 270/796 | TaqMan | Yes |
| He30 | 2 | 2010 | USA | Caucasian | PB | NA | Melanoma | 211/796 | TaqMan | Yes |
| He30 | 3 | 2010 | USA | Caucasian | PB | NA | SCC | 266/796 | TaqMan | Yes |
| Ho31 | 2006 | China | Asian | HB | NA | Lung cancer | 230/240 | PCR-RFLP | Yes | |
| Kakkoura15 | 2015 | Cyprus | Caucasian | PB | Yes | Breast cancer | 1057/1141 | TaqMan | Yes | |
| Karunasinghe16 | 2012 | New Zealand | Caucasian | HB | NA | Prostate cancer | 258/434 | TaqMan | Yes | |
| Koistinen32 | 2006 | Finland | Caucasian | NA | Yes | AML | 89/NA | PCR | NA | |
| Li33 | 2009 | USA | Caucasian | PB | Yes | Breast cancer | 497/493 | TaqMan | Yes | |
| Lightfoot34 | 2006 | USA/UK | Caucasian | PB | NA | NHL | 928/1446 | TaqMan | Yes | |
| Liu35 | 2015 | China | Asian | PB | Yes | Hepatocellular carcinoma | 266/248 | PCR-RFLP | Yes | |
| Nahon36 | 2009 | France | Caucasian | NA | NA | Hepatocellular carcinoma | 190/NA | PCR | NA | |
| Quick37 | 1 | 2008 | USA | Mixed | PB | Yes | Breast cancer | 57/108 | MALDI-TOF | Yes |
| Quick37 | 2 | 2008 | USA | Caucasian | PB | Yes | Breast cancer | 569/974 | MALDI-TOF | Yes |
| Rajaraman8 | 1 | 2008 | USA | Mixed | HB | Yes | Acoustic neuroma | 69/494 | TaqMan | Yes |
| Rajaraman8 | 2 | 2008 | USA | Mixed | HB | Yes | Glioma | 362/494 | TaqMan | Yes |
| Rajaraman8 | 3 | 2008 | USA | Mixed | HB | Yes | Meningioma | 134/494 | TaqMan | Yes |
| Saadat38 | 2015 | Iran | Caucasian | PB | NA | Breast cancer | 407/395 | PCR | Yes | |
| Su11 | 2015 | China | Asian | HB | Yes | Hepatocellular carcinoma | 400/480 | PCR-RFLP | Yes | |
| Tang39 | 2010 | USA | Mixed | HB | NA | Pancreatic cancer | 551/602 | TaqMan | Yes | |
| Tefik18 | 2013 | Turkey | Caucasian | HB | NA | Prostate cancer | 155/195 | PCR | Yes | |
| Tsai40 | 2012 | China | Asian | HB | Yes | Breast cancer | 260/224 | PCR | Yes | |
| Ulder41 | 2007 | England | Caucasian | PB | Yes | Breast cancer | NA | TaqMan | NA | |
| Van Blarigan42 | 2014 | USA | Caucasian | PB | NA | Prostate cancer | NA | MALDI-TOF | NA |
*Number of data separately reported by articles.
HWE: Hardy-Weinberg equilibrium; MALDI-TOF: Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PB: population-based; HB: hospital-based; NA: not available. CML: Chronic myeloid leukemia; NHL: non-Hodgkin lymphoma; BCC: Basal cell carcinoma; SCC: Squamous cell carcinoma; AML: Acute myeloid leukemia.